Dishman Carbo Amcis Ltd

DCAL NSE Healthcare Pharmaceuticals
₹167.25
-0.14%
Delayed · cached 15 min

Fair value analysis

DCAL
Dishman Carbo Amcis Ltd
HealthcarePharmaceuticals
₹167.49
Close used for this calculation
₹255.25Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
33/100
Profitability4/25
Returns10/25
Balance Sheet17/25
Efficiency2/25
Growth8/25
Weak
Quality radar
33Prof.4/25Ret.10/25Eff.2/25B.Sht17/25Growth8/25

Consensus fair value

₹255.25
Below FV
▲ +52.4% against the close used
Model range ₹12.48 – ₹381.61
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹12.48Fair value₹255.25Bull₹381.61
FairClose
52-week traded range
52W low ₹129.9752W high ₹314.40

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading below the consensus fair value

Dishman Carbo Amcis Ltd closed at ₹167.49, 34.4% below the consensus fair value of ₹255.25 drawn from 7 valuation models.

Financial DNA score 33/100 — Weak. P/E of 145.0x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
₹269.38
+60.8%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
Graham Number
₹105.15
-37.2%
√(22.5 × EPS × BVPS)
EPS=6.22, BVPS=79 · outside Graham range (P/E 145, P/B 2.1) — asset-light, treat as a rough floor
P/E Fair Value
₹222.05
+32.6%
EPS × 35.7x (sector P/E)
EPS=6.22, Sector P/E=35.7x
EV/EBITDA
₹381.61
+127.8%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=9.05B
Book Value (P/B)
₹12.48
-92.5%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=79, ROE=1.6%, g=3%, r=10%
Reverse DCF
₹167.49
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 11.2% | Historical: 0%
Margin of Safety
₹149.14
-11.0%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=198.86, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.